Patrick A. Ott
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 179
- Cancer Immunotherapy and Biomarkers 146
- CAR-T cell therapy research 55
- Colorectal Cancer Treatments and Studies 15
- Cutaneous Melanoma Detection and Management 14
- Immunology 80
- Immunotherapy and Immune Responses 71
- Co-authors
- F. Stephen Hodi (59 shared papers)Catherine J. Wu (13 shared papers)Eryn Blass (1 shared paper)Zhuting Hu (3 shared papers)Jason J. Luke (21 shared papers)Caroline Robert (3 shared papers)Sarina A. Piha‐Paul (16 shared papers)Sanatan Saraf (9 shared papers)
- Journals
- Journal of Clinical Oncology (69 papers)Journal for ImmunoTherapy of Cancer (20 papers)Annals of Oncology (18 papers)Cancer Immunology Research (11 papers)Clinical Cancer Research (8 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Patrick A. Ott
239 papers receiving 16.0k citations
Patrick A. Ott's Hit Papers
Peers
Comparison fields: 5 of 127
- Oncology 10.0k
- Immunology 5.0k
- Pulmonary and Respiratory Medicine 2.7k
- Obstetrics and Gynecology 452
- Cancer Research 876
Countries citing papers authored by Patrick A. Ott
This map shows the geographic impact of Patrick A. Ott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick A. Ott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick A. Ott more than expected).
Fields of papers citing papers by Patrick A. Ott
This network shows the impact of papers produced by Patrick A. Ott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick A. Ott. The network helps show where Patrick A. Ott may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick A. Ott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 245 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Towards personalized, tumour-specific, therapeutic vaccines for cancer Hit paper breakdown → | 2017 | 823 |
| 2 | Advances in the development of personalized neoantigen-based therapeutic cancer vaccines Hit paper breakdown → | 2021 | 744 |
| 3 | T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028 Hit paper breakdown → | 2018 | 681 |
| 4 | CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients Hit paper breakdown → | 2013 | 572 |
| 5 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial Hit paper breakdown → | 2016 | 525 |
| 6 | CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer Hit paper breakdown → | 2018 | 482 |
| 7 | Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors Hit paper breakdown → | 2016 | 471 |
| 8 | Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy Hit paper breakdown → | 2016 | 408 |
| 9 | Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial Hit paper breakdown → | 2017 | 405 |
| 10 | Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study Hit paper breakdown → | 2017 | 385 |
| 11 | Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients Hit paper breakdown → | 2017 | 381 |
| 12 | 2012 | 375 | |
| 13 | PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course Hit paper breakdown → | 2016 | 375 |
| 14 | Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma Hit paper breakdown → | 2017 | 373 |
| 15 | Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study Hit paper breakdown → | 2017 | 372 |
| 16 | 2017 | 311 | |
| 17 | Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies Hit paper breakdown → | 2016 | 277 |
| 18 | 2018 | 270 | |
| 19 | Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study Hit paper breakdown → | 2018 | 269 |
| 20 | 2014 | 227 |
About Patrick A. Ott
Patrick A. Ott is a scholar working on Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine and Surgery, having authored 245 papers that have together received 16.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (146 papers), Immunotherapy and Immune Responses (71 papers), CAR-T cell therapy research (55 papers), Melanoma and MAPK Pathways (31 papers), vaccines and immunoinformatics approaches (18 papers), Monoclonal and Polyclonal Antibodies Research (16 papers), Colorectal Cancer Treatments and Studies (15 papers) and Cutaneous Melanoma Detection and Management (14 papers). The work is most often cited by research in Oncology (10.0k citations), Immunology (5.0k citations), Pulmonary and Respiratory Medicine (2.7k citations), Obstetrics and Gynecology (452 citations) and Cancer Research (876 citations). Patrick A. Ott has collaborated with scholars based in United States, France and Germany. Frequent co-authors include F. Stephen Hodi, Catherine J. Wu, Eryn Blass, Zhuting Hu, Jason J. Luke, Caroline Robert, Sarina A. Piha‐Paul, Sanatan Saraf, Jedd D. Wolchok and Anna C. Pavlick. Their work appears in journals such as Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Annals of Oncology, Cancer Immunology Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.